Various laboratory protocols for measuring thromboxane A2 generation to detect the effectiveness of acetylsalicylic acid therapy: A comparative study

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 1, 2014, Pages 46-51

  Rozalski, Marcin ^a   Watala, Cezary ^a   Golanski, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

acetylsalicylic acid; antiplatelet acetylsalicylic acid; antiplatelet therapy; aspirin resistance; thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; POLOCARD; THROMBOXANE A2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; ELECTRODE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; THROMBOCYTE AGGREGATION;

ADULT; ASPIRIN; BLOOD CHEMICAL ANALYSIS; BLOOD COAGULATION; FEMALE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE A2;

EID: 84893676593     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32836551b5     Document Type: Article

References (33)

1. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012; 141:e89S-e119S.
2. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso- Coello P, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S-e668S.
3. Perk J, De BG, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33:1635-1701.
4. Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Doesch C, Bigalke B, et al. Residual platelet activity is increased in Clopidogreland ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2007; 94:743-747.
5. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167:1593-1599.
6. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events: a metaanalysis. Int J Cardiol 2008; 128:166-171.
7. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ''resistance'' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336:195-198.
8. Brister SJ, Buchanan MR. Aspirin 'resistance' and its impact on cardiovascular morbidity and mortality: it is real, clinical relevant and should be measured. Heart 2009; 95:1223-1224.
9. Aydinalp A, Atar I, Gulmez O, Atar A, Acikel S, Bozbas H, et al. The clinical significance of aspirin resistance in patients with chest pain. Clin Cardiol 2010; 33:E1-E7.
10. Salama MM, Morad AR, Saleh MA, Sabri NA, Zaki MM, ElSafady LA. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. J Clin Pharm Ther 2012; 37:630-636.
11. Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Clin Neurol Neurosurg 2009; 111:270-273.
12. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, et al. Antiplatelet therapy and platelet function testing. Clin Cardiol 2008; 31:I36.
13. Can MM, Tanboga IH, Turkyilmaz E, Karabay CY, Akgun T, Koca F, et al. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res 2010; 125:e132-e137.
14. Kim KE, Woo KS,Goh RY, Quan ML, Cha KS, Kim MH, et al. Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. Int J Lab Hematol 2010; 32:50-55.
15. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30:426-435.
16. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28:1702-1708.
17. Lotrionte M, Biondi-Zoccai GG, Agostoni P, Sheiban I. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic. Eur Heart J 2007; 29:138-139.
18. Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 2009; 95:1225-1229.
19. Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009; 131:834- 842.
20. Postula M, Tarchalska-Krynska B, Filipiak KJ, Kosior D, Serafin A, Huczek Z, et al. Factors responsible for ''aspirin resistance'': can we identify them? Kardiol Pol 2010; 68:403-411.
21. VidaliM, Rolla R, Parrella M, Cassani C, Manzini M, Portalupi MR, et al. Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol 2012; 34:484-494.
22. Nocun M, Ulicna O, Muchova J, Durackova Z, Watala C. French maritime pine bark extract (Pycnogenol((R))) reduces thromboxane generation in blood from diabetic male rats. Biomed Pharmacother 2007.
23. Watala C, Golanski J, Wieclawska B, Boncler M. Use of flow cytomery to differentiate between activation and reactivity of blood platelets: methodological report. Med Sci Monit 2013; 5:154-161.
24. Lellouche F, Fradin A, Fitzgerald G, Maclouf J. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins 1990; 40:297-310.
25. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96:781-788.
26. Golanski J, Golanski R, Iwaszkiewicz A, Chlopicki S, Gresner P, Watala C. Resistance to aspirin in patients after coronary artery bypass grafting is transient. Impact on the monitoring of aspirin antiplatelet therapy. Therap Drug Monit 2005; 27:484-490.
27. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, et al. Assessing the current role of platelet function testing. Clin Cardiol 2008; 31:I10-I16.
28. Kidson-Gerber G, Weaver J, Gemmell R, Prasan AM, Chong BH. Serum thromboxane B2 compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. Heart Lung Circ 2010; 19:234-242.
29. Patrono C, Ciabattoni G, Pugliese F, Pinca E, Castrucci G, De Salvo A, et al. Radioimmunoassay of serum thromboxane B2: a simple method of assessing pharmacologic effects on platelet function. Adv Prostaglandin Thromboxane Res 1980; 6:187-191.
30. Larsen SB, Neergaard-Petersen S, Grove EL, Kristensen SD, Hvas AM. Increased platelet aggregation and serum thromboxane levels in aspirintreated patients with prior myocardial infarction. Thromb Haemost 2012; 108:140-147.
31. Velik-Salchner C, Maier S, Innerhofer P, Streif W, Klingler A, Kolbitsch C, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008; 107:1798-1806.
32. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110:e489-e493.
33. Santilli F, Rocca B, De CR, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin ''resistance''. J Am Coll Cardiol 2009; 53:667-677.